The new site will be used for the storage of contingency stocks of European Pharmacopoeia reference standards for distribution worldwide in case of major incidents at its main site in Strasbourg, France.
European Directorate for the Quality of Medicines (EDQM) opened a secondary site in Ars-Laquenexy, France, on Nov. 15, 2019 for the storage of contingency stocks of European Pharmacopoeia reference standards for distribution worldwide in case of major incidents at its main site in Strasbourg, France.
According to a company press release, the new site is part of EDQM’s goal to create a full backup stock of European Pharmacopoeia reference standards in order to combat a potential supply shortage, which would result in the blockage of certain medicines from European and non-European markets. In 2018, over 1.6 million vials of reference standards were produced to build up the stock for the new site.
The new site has 2770 m2 of floor area with designated space for preparation of samples required for laboratory studies carried out during the development of monographs and the establishment of reference standards, according to the release. The space also has the storage capacity for 9.4 million vials and 378 pallets.
“The reference standards produced by the EDQM are fundamental to guarantee that all patients in Europe and beyond have uninterrupted access to the good-quality medicines they need,” said SnezÌana SamardzÌicÌ-MarkovicÌ, director general of democracy of the Council of Europe, in the press release.
Source:
EDQM
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.